天演药业上涨14.37%，报1.91美元/股，总市值9002.07万美元

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) has experienced a significant stock price increase of 14.37% on December 16, reaching $1.91 per share, with a total market capitalization of $90.02 million, despite reporting a substantial decline in revenue and net profit for the fiscal year ending December 31, 2024 [1]. Financial Performance - The total revenue for Tianyan Pharmaceuticals is reported at $103,200, reflecting a year-over-year decrease of 99.43% [1]. - The net profit attributable to the parent company is reported at -$33.42 million, which represents a year-over-year decrease of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company listed on NASDAQ under the ticker ADAG, focused on the development of clinical products driven by its proprietary platform [1]. - The company aims to discover and develop novel cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1].